Zimovane

Quick links to important sections

Zimovane

Method of action: Hypnotic

Treatment option: Insomnia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zimovane

Quick Facts

Property Description
Active ingredient Zopiclone
Form Tablet (Film-coated tablet)
Pharmacological class Sedative-hypnotic (Z-drug)
Common use Sleep disorder medication
Origin Synthetic compound (Cyclopyrrolone derivative)

Defining Zimovane: Active Substance and Pharmacological Class

Zimovane is a prescription-only medicine (POM) defined by its active ingredient, Zopiclone, which is supplied for oral administration typically as a single active ingredient film-coated tablet. The compound is a synthetic compound chemically classified as a cyclopyrrolone derivative. This identity places it within the broader sedative-hypnotic pharmacological class, a grouping clinically recognized for its ability to induce and maintain rest.

What Type of Drug is Zopiclone? (The Z-Drug Classification)

Zopiclone is primarily categorized as a powerful hypnotic agent and belongs to the non-benzodiazepine group, colloquially known as a "Z-drug." This drug classification is a key differentiator, signifying that while it shares the therapeutic goal of older Benzodiazepines, its unique structure provides a distinct pharmacological profile. Zopiclone is described as possessing the necessary qualities of a tranquilizer-hypnotic while exhibiting different characteristics concerning secondary effects. The mechanism of effect involves positively modulating the GABAergic system by selectively binding to sites on the GABAA receptor.

General Purpose of this Hypnotic

The overriding purpose of this medication is to serve as a sleep disorder medication for adult patients. As a potent hypnotic, its general utility is centered on reducing the time required to fall asleep and improving the continuity of sleep, which is a key therapeutic goal for individuals with insomnia. Zopiclone is used to improve various parameters of sleep. By acting as a CNS depressant, the drug's fundamental function is to chemically assist the body in achieving the necessary tranquility for rest.

Regulatory References

  1. Clinical Overview

What side effects are possible with Zimovane?

Possible Side Effects and Safety Information

The safety profile for Zimovane (Zopiclone) is defined by officially documented adverse reactions categorized by their frequency and the physiological system affected. The most frequently reported effects, classified as Common, include dysgeusia (a bitter taste), residual somnolence or drowsiness, and dry mouth. Effects such as dizziness, headache, nausea, vomiting, and fatigue are generally classified as Uncommon.


Serious Adverse Reactions and Safety Constraints

Official regulatory labeling documents certain risks that are less frequent but clinically significant. These Serious Adverse Reactions include very rare reactions such as anaphylactic reaction and angioedema. The label also notes the potential for Complex sleep behaviours—such as sleep-driving or somnambulism—and respiratory depression (frequency not known).

Key safety constraints exist regarding duration and specific populations. The risk of developing dependence and experiencing withdrawal syndrome increases with the duration of treatment, particularly with use extending beyond four weeks. Anterograde amnesia is documented as a rare reaction that may be more likely if sleep is interrupted or delayed after taking the tablet. Furthermore, the medicine is contraindicated for patients with severe hepatic insufficiency, and caution is required for older adults due to an increased risk of falls and paradoxical reactions. Concomitant use with other Central Nervous System (CNS) depressants may significantly enhance the risk of respiratory depression and adverse outcomes.

Overdose and Emergency Response

The Zimovane overdose profile, as documented by regulatory authorities, centers on the manifestations of Central Nervous System (CNS) depression. Presentations can range from milder symptoms such as drowsiness, lethargy, and confusion to more severe clinical signs, including ataxia, hypotonia, and hypotension. Severe outcomes documented in official labeling include respiratory depression and progression to coma.

When to Seek Immediate Medical Help

Regulatory instruction mandates that immediate medical attention must be sought for any suspected overdose. Emergency services should be contacted without delay, particularly for severe manifestations or progression of symptoms.

Documented Risks and Management

A fatal outcome is explicitly noted to be most likely when Zopiclone is co-ingested in overdose with other CNS depressants, such as alcohol or opioids. The severity of symptoms may also be heightened by the presence of concomitant illness or a debilitated state.

Management is officially defined as symptomatic and supportive treatment, with continuous attention paid to respiratory and cardiovascular functions. The antagonist flumazenil is noted as a potential antidote, although its use carries documented risks of inducing neurological symptoms. Regulatory documents also clarify that hemodialysis is of no value in treatment.

Therapeutic Uses of Zimovane

Zimovane (Zopiclone) is a medication generally applied for the short-term symptomatic management of distressing insomnia in adult patients. It is used across domains where additional symptomatic support is needed, helping patients cope more steadily with episodes that interfere with daily functioning. It is classified as a type of sleeping pill indicated for short-term treatment.


The medication is relevant for easing groups of symptoms that may become intense or disruptive, commonly including difficulty initiating sleep, frequent nighttime awakenings, and early final awakening. Zimovane is applied in clinical settings that involve acute or unstable symptom patterns, such as transient or situational insomnia related to temporary stress or schedule changes.

Therapeutic Focus and Benefit

The primary therapeutic focus is the support provided in helping to ease the time required to fall asleep and contributing to maintaining a sense of stability during rest. The use of this agent is relevant for easing symptoms that interfere with daily functioning and create noticeable functional strain. This supportive relief contributes to easing the overall symptom load associated with fragmented sleep.

“The goal is to apply assistance for patients who experience difficult episodes, which may help maintain a sense of stability.”

It is often used when symptoms intensify and supportive relief is needed to address acute or disruptive sleep patterns. This is applied to assist patients who experience difficult episodes, which may help maintain a sense of stability.

Quick Fact: Support for Sleep Disturbance Symptoms
Symptom Category Symptoms that create noticeable functional strain.
Primary Use Context Conditions characterized by periods of heightened, temporary sleep symptoms.
Patient Benefit Assists with maintaining functional stability by easing sleep latency and fragmented rest.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zimovane?

The official regulatory profile for Zimovane strictly defines population eligibility based on absolute contraindications and mandatory restrictions as documented in prescribing information.

Category Eligibility Status (Regulatory Wording)
Contraindicated Groups Use is prohibited in patients with Severe Hepatic Insufficiency, Myasthenia Gravis, Severe Respiratory or Sleep Apnoea Syndrome, or prior experience of Complex Sleep Behaviors after Zopiclone use.
Age Exclusion Contraindicated in children and adolescents (under 18 years) as safety and efficacy have not been established; use is approved only for Adults.
Conditional Use Older Adults and patients with non-severe Renal Impairment or Chronic Respiratory Insufficiency are directed to a reduced starting dose.
Reproductive Status Use is Not Recommended during pregnancy or breastfeeding.
Restriction Extreme Caution is required for patients with a history of alcohol or drug abuse due to increased risk of dependence.

The regulatory classifications formally establish clear, non-negotiable prohibitions for groups with specific high-risk comorbidities and completely exclude the pediatric age group. Eligibility for others is limited by age and impaired organ function, which require a mandatory restriction, such as a lower starting condition, as defined by official regulatory bodies.

What should I know about interactions with other medicines?

The official regulatory profile for Zimovane's interactions centers on two domains: pharmacodynamic potentiation of central effects and pharmacokinetic modification of drug levels.

Interactions with Central Nervous System Depressants

The central depressive effect of Zimovane is enhanced when co-administered with other Central Nervous System (CNS) depressants. This documented category includes antipsychotics, anxiolytics, sedative antihistamines, and narcotic analgesics. The combination of Zimovane with Opioids carries a formal regulatory restriction due to the heightened risk of profound sedation, respiratory depression, coma, and death. Concomitant use of alcohol is officially discouraged as it significantly intensifies the sedative effect, which may increase the risk of psychomotor impairment.

Metabolic Interactions (CYP3A4)

Zimovane exposure is highly sensitive to substances that alter the activity of the CYP3A4 liver enzyme, which is primarily responsible for its metabolism. Agents that inhibit this enzyme, such as Erythromycin and Itraconazole, cause a documented increase in Zimovane's plasma concentration, potentially enhancing its hypnotic effect. Conversely, strong enzyme inducers, including Rifampicin and the herbal product St. John's Wort, reduce the drug's plasma concentration, resulting in a substantially lower therapeutic effect. Regulatory documents also note that elderly patients may exhibit increased sensitivity to the enhanced effects resulting from co-administration with CYP3A4 inhibitors.

Mechanism of Action

Modulation of GABA A Receptor Signaling

Zimovane acts within domains involving receptor-mediated signaling by binding allosterically to a specific non-benzodiazepine site on the central nervous system's GABA A receptor complex. This GABA A receptor agonism is the primary mechanistic cascade that initiates the drug's effects. This action enhances the intrinsic effect of the inhibitory neurotransmitter GABA.


Increasing Chloride Ion Conductance

The binding of Zimovane to the GABA A receptor modifies early molecular steps by facilitating the opening frequency of the associated chloride ion Cl^- channel. This increase in Cl^- ion flow across the neuronal membrane causes hyperpolarization of the neuron, rendering it less susceptible to excitatory input and dampening nerve transmission.


Depression of Central Nervous System Activity

The resulting physiological consequence is a generalized depression of central nervous system (CNS) activity. This effect establishes an augmented inhibitory state within targeted physiological pathways by broadly reducing neuronal excitability, resulting in physiological adjustments characteristic of enhanced central inhibition, which dictates the systemic neurophysiological effects.


Targeting Key Neural Arousal Pathways

The drug's activity is relevant in systems where specific transmitters or mediators dominate, selectively acting on GABA A receptors predominantly found in brain areas like the cerebral cortex, cerebellum, and limbic system, structures involved in arousal regulation. This facilitates a shift toward reduced neuronal excitation governing states of neural excitability.

Dosage and Administration Information

How Zimovane is Used: Official Administration Guidelines

Zimovane (Zopiclone) is provided as a film-coated tablet for oral administration only. Standard clinical protocols outline the dosing, schedule, and duration of use, emphasizing the need to use the lowest effective dose for the shortest time possible.

Official Dosing and Schedule

Instruction Entity Clinical Parameters
Route of Administration Oral use only. The tablet must be swallowed whole.
Standard Adult Dose 7.5 mg once daily shortly before retiring. This dose should not be exceeded.
Dosing Frequency A single intake per night; must not be re-administered during the same night.
Timing Constraint Must be taken only when a full night’s sleep (approximately 7–8 hours) can be achieved.

Duration and Specific Population Rules

Treatment duration should be as short as possible and typically not exceed four weeks, which includes any necessary period of gradual dose reduction (tapering).

Specific dosage modifications are generally recommended for vulnerable groups to mitigate the risk of accumulation:

  • Older Adults (Elderly): The recommended initial dose is 3.75 mg nightly.
  • Hepatic or Renal Impairment: A starting dose of 3.75 mg nightly is recommended due to potential changes in drug clearance.
  • Pediatric Population: Use is not recommended in children and adolescents under 18 years, as safety and efficacy have not been established.

This protocol describes the framework for the use of the medicine around a single, fixed nightly dose and a specific time limit for treatment, ensuring administration adheres precisely to established parameters.

Recent Clinical Evidence

Research Evidence Overview: Studies for Zimovane (Zopiclone)


Evidence for Short-Term Insomnia (Difficulty Falling and Staying Asleep)

Zimovane was studied for short-term randomized controlled trials (RCTs). These studies compare patients who were given the medication against those who received an inactive treatment (placebo). The outcomes related to sleep were measured using both patient-reported experiences (subjective outcomes) and objective tools, like sleep laboratory measurements (polysomnography). The populations evaluated were mainly adults (ages 18–65) with a diagnosis of short-term insomnia.

Studies monitored measured outcomes related to how quickly participants fell asleep (sleep onset latency) and the total amount of time they spent asleep during the measured period. Research also explored outcomes related to daily functioning and patient-reported outcomes describing perceived discomfort, based on patient questionnaires. These measurements were focused heavily on the initial weeks of use, which contributes to the broader evidence landscape but does not provide long-term data.


Comparative Study Patterns Against Placebo and Other Treatments

The research has explored studies where Zimovane was evaluated in comparison to an inactive pill (placebo) and, in some cases, against other medications used for short-term insomnia. These comparative studies were conducted during periods of increased symptom activity, primarily focusing on short-term symptom changes in sleep patterns.

Studies monitored various outcomes reflecting sleep maintenance, such as the number of awakenings during the night. Studies report how symptoms evolved in the observed populations, noting patterns related to measured differences in these outcomes when compared to placebo. However, evidence quality varies across studies, and comparative evidence against every type of alternative treatment may be lacking.


What Research Still Shows Uncertainty and Gaps

There are several areas where the available research provides limited insight or where data is still emerging. The vast majority of the clinical research for Zimovane consists of trials with follow-up durations that were limited, typically lasting only four to six weeks.

Long-term outcomes are not fully established through controlled research, particularly regarding the durability of any initial patterns described in short-term trials. Data for certain groups, such as children, pregnant populations, or individuals with specific complex comorbidities, remain insufficient or limited. The existing evidence base has limitations where sample sizes were modest in several key trials, and comparative evidence is lacking.

Key Studies & References

  1. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation - NCBI
  2. Assessment report: The clinical and cost-effectiveness of zaleplon, zolpidem and zopiclone for the management of insomnia - NICE
  3. Zopiclone - Wikipedia (General Information and Safety Profile)

Frequently Asked Questions (FAQ)

Common questions about Zimovane (FAQ)

Q: How quickly does Zimovane start to work after taking it?

Official patient information indicates that Zimovane generally starts to have an effect around one hour after it is taken. Regulatory guidance indicates that the medication is intended to be taken only immediately before retiring for the night.


Q: How long does the effect of Zimovane typically last?

Studies and official product information describe the way the body handles the drug, noting that the elimination half-life of the unchanged active ingredient is approximately 5 hours in adults. The half-life describes the time it takes for the concentration of the medication in the body to drop by half.


Q: Can Zimovane cause drowsiness the next day?

Yes, residual somnolence (drowsiness) is officially documented as a common side effect. Regulatory warnings mention the importance of considering impairment when performing activities that require full mental alertness, such as driving.


Q: Are there any common foods or drinks that should be avoided when taking Zimovane?

Regulatory documents explicitly advise against consuming alcohol, as it can significantly enhance the sedative effects of the medication. While specific foods are not usually listed as forbidden, some official patient information notes that substances like caffeine may potentially diminish the effectiveness of the drug.


Q: Can Zimovane be taken with common pain relievers like ibuprofen?

Official guidance specifically warns against combining Zimovane with medicines that also have Central Nervous System (CNS) depressant effects, such as opioid-based painkillers. Non-narcotic pain relievers like ibuprofen are typically not classified this way, but information on specific combinations should be reviewed by a prescribing healthcare professional.


Q: Is there a taste alteration commonly associated with Zimovane?

Yes, dysgeusia (a taste disturbance) is officially listed as a common side effect. This taste alteration is often described in regulatory patient information as a distinct bitter or metallic aftertaste.


Q: Does Zimovane interact with alcohol?

Yes, official prescribing information states that combining Zimovane with alcohol is not recommended. Alcohol can significantly increase the sedative effect of the medication, a situation associated with impaired coordination and heightened risk of impairment.


Q: Can Zimovane be taken if I have a history of depression?

Official documents require extreme caution when considering use in patients with a history of psychiatric disorders. Regulatory warnings note that some studies show an increased incidence of suicidal thoughts in patients treated with hypnotics, including zopiclone, regardless of whether they have a history of depression.


Q: Are there any withdrawal symptoms associated with stopping Zimovane?

Yes, official safety information indicates that if physical dependence has developed, suddenly stopping the medication may lead to a withdrawal syndrome. Symptoms that may occur include anxiety, restlessness, confusion, irritability, and, in severe cases, more complex mental and sensory disturbances.


Q: What happens if I miss a dose of Zimovane?

Official patient information states that Zimovane should not be taken later in the night if an occasional dose is missed. This medication is intended to be taken only when a person can ensure they will get a full night's sleep, typically 7–8 hours.


Q: How does Zimovane differ from other 'Z-drugs'?

Zimovane (zopiclone) belongs to the 'Z-drug' pharmacological class, which are non-benzodiazepines that work on the same central receptor system. While they share the therapeutic goal of inducing sleep, these drugs have different chemical structures and may show variations in their duration of action, such as zopiclone's approximately 5-hour elimination half-life.


Q: Is Zimovane excreted in breast milk?

Studies have confirmed that the active ingredient, zopiclone, is excreted into breast milk. Because of this, official regulatory guidance explicitly states that the use of Zimovane is not recommended during the breastfeeding period.


Q: What official classification does Zimovane have in my country?

In most countries with regulatory oversight, Zimovane (zopiclone) is classified as a prescription-only medicine (POM). Due to its potential for dependence, it is also designated as a controlled substance (e.g., Schedule IV in the US, Class C in the UK) under drug control legislation.


Q: Are there different strengths or formulations of Zimovane available?

Zimovane is most commonly available as a film-coated tablet in multiple strengths, which often include 3.75 mg and 7.5 mg. These different strengths are available to align with official prescribing rules for various patient needs.


Q: Is Zimovane available without a prescription anywhere?

No, Zimovane (zopiclone) is uniformly classified as a prescription-only medicine in countries with formal regulatory bodies. It is not available for purchase over-the-counter.


Q: Can Zimovane cause unusual dreams or nightmares?

Official safety documents list nightmares as a possible side effect of the medication. Other psychiatric and paradoxical reactions, such as hallucinations and unusual behavior, have also been reported.


Q: Does taking Zimovane affect my breathing?

Yes, Zimovane has the capacity to act as a respiratory depressant, meaning it can slow down breathing. Regulatory warnings are issued regarding the risk of respiratory depression, especially when the drug is taken by people with existing respiratory problems or in combination with other Central Nervous System depressants.


Q: Is Zimovane a hypnotic or a sedative?

Zimovane is officially classified as a sedative-hypnotic medicine. A hypnotic is a drug whose main purpose is to induce and maintain sleep, which is its primary function.


Q: Can Zimovane be taken at the same time as my blood pressure medication?

Official regulatory information focuses on specific interactions with CNS depressants and liver enzyme inhibitors/inducers. There are no general contraindications for all blood pressure medications as a class, but a healthcare professional is needed to review all co-administered medicines for potential interactions.


Q: Can Zimovane cause a metallic taste?

Yes, official patient information explicitly describes the common side effect of dysgeusia (a taste disturbance) as often feeling like a bitter or metallic taste.


Q: Is Zimovane used for jet lag?

The approved use of Zimovane in regulatory labeling is strictly for the short-term treatment of insomnia in adults. While some physicians may use it for symptoms like jet lag, this specific condition is not listed as an official indication in the core regulatory documents.


Q: How do researchers measure the effectiveness of Zimovane?

The effectiveness of the medication is measured in clinical trials using both patient reports (subjective outcomes) and objective laboratory tests, such as polysomnography. Key measurements include how quickly participants fall asleep (sleep onset latency) and their total sleep time.


Q: How is Zimovane cleared from the body?

The drug is primarily broken down (metabolized) in the liver by the CYP3A4 enzyme system. The resulting by-products are then cleared from the body, mostly through urine and, to a lesser extent, through faeces.


Q: Are there any dietary restrictions specifically mentioned for Zimovane?

The most significant restriction noted in official documents is the absolute warning against using alcohol due to the enhanced sedative effect. There are no general regulatory restrictions on specific food groups, but some official patient information mentions that drinks containing caffeine may potentially diminish the medication's effect.

How should Zimovane be stored and disposed of?

How to Store and Dispose of Zimovane (Zopiclone)

Official regulatory documents define strict conditions for the storage and disposal of Zimovane tablets.

Storage Requirements

Requirement Description
Temperature Store below 25 C to maintain product stability.
Protection Must be protected from light, moisture, sunlight, and heat.
Packaging Keep the tablets in the original container and the outer carton to ensure protection.
Child Safety Store strictly out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Authorities generally recommend utilizing authorized drug take-back programs where available. Medicines should not be disposed of via household wastewater or flush systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zimovane found in:

A-Z Index: